Junshi Biosciences of Shanghai and its US partner Coherus Bio reported their PD-1 candidate was granted a second Breakthrough Therapy Status in the US . Toripalimab, the anti-PD-1 discovered by Junshi, was awarded BTK as a first-line therapy in nasopharyngeal carcinoma in combination with chemotherapy. Previously, it received BTD for second-line NPC as a single agent. Earlier this year, Junshi out-licensed US/Canada rights for toripalimab to Coherus in a $1.1 billion deal. More details.... Stock Symbols: (HK: 1877; SHA: 688180) (NSDQ: CHRS) Share this with colleagues: // //